shutterstock_1169047330_markvanscyoc-1
markvanscyoc / shutterstock.com
7 October 2021AmericasMuireann Bolger

LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
19 May 2022   The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
19 May 2022   The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.
Americas
19 May 2022   The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.